Glenmark Pharmaceuticals

World Water Day is a reminder that saving water is a shared responsibility. As we work toward becoming water-neutral by this year, our approach goes beyond reducing consumption. We have optimised processes with automated sensors, steam condensate recovery, and raw-water RO reject reuse to minimise waste. Our conservation efforts include rainwater harvesting, wastewater treatment, water recovery and recycling of treated water to ensure every drop is used efficiently. Beyond our operations, we actively support communities through water conservation initiatives. True sustainability isn’t just about using less; it’s about giving back more than we take. #Glenmark #GlenmarkPharmaceuticals #WorldWaterDay

This #WorldForestDay, we’re reflecting on the impact of our ongoing efforts to create a greener, healthier world. Through our green initiatives, we have planted over 53,000 trees across various locations globally. We continue to work towards creating urban forests to improve air quality, combat pollution, restore biodiversity, and create spaces for communities to thrive. Every tree planted is a step toward a more sustainable future, and we’re proud to be part of that journey. #Glenmark #GlenmarkPharmaceuticals #ForestDay

We are happy to announce that Glenmark Pharmaceuticals Inc., our US subsidiary, has received final approval by the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), determined by the FDA to be bioequivalent to Pataday® Once Daily Relief Ophthalmic Solution, 0.2% (OTC), of Alcon Laboratories, Inc. To know more about this announcement, please visit: https://bit.ly/4bTsWDp

Glenn Saldanha: Chairman and Managing Director of Glenmark Pharmaceuticals 1️⃣ 🌟 Transformational Leadership: As Chairman and Managing Director of Glenmark Pharmaceuticals, Glenn Saldanha has spearheaded the company’s innovation journey for over 26 years, redefining healthcare solutions globally. 2️⃣ 🎓 Stellar Foundation: With an MBA from NYU Stern and a Bachelor’s in Pharmacy from the University of Mumbai, Glenn’s education combines business acumen with pharmaceutical expertise. 3️⃣ 🌐 Global Influence: Under his leadership, Glenmark has expanded its footprint across continents, delivering cutting-edge therapies and contributing to global health with a focus on unmet patient needs. 4️⃣ 🔬 Disruptive Innovations: Glenn is committed to challenging the medical status quo by driving discovery and development, ensuring the creation of novel treatments for a wide array of diseases. 5️⃣ 🏆 Decorated Career: His honors include the EY Entrepreneur of the Year Award, India Pharma Leader Award, and recognition among the Top 50 CEOs in India, reflecting his exceptional leadership and impact. 6️⃣ 💡 Operational Excellence: Over two decades, Glenn has steered Glenmark toward operational efficiency and sustainable growth, making it a trusted name in pharmaceuticals worldwide. 7️⃣ 🤝 Global Partnerships: From his early days at PwC and Eli Lilly, Glenn developed a deep understanding of international markets, which he leveraged to forge strategic alliances and expand Glenmark’s global presence. 8️⃣ 🚀 Pioneering Solutions: Under his guidance, Glenmark has focused on innovative therapies in oncology, dermatology, and respiratory health, enhancing patient outcomes and quality of life. 9️⃣ 🌍 Philanthropic Impact: Glenn’s leadership extends beyond business, with Glenmark actively supporting healthcare access and community well-being initiatives worldwide. 🔟 🌟 Inspiring the Future: Glenn Saldanha’s visionary leadership continues to inspire the pharmaceutical industry, positioning Glenmark as a beacon of innovation and excellence in healthcare. #Innovation #Leadership #PharmaExcellence #GlobalHealth ------------------------------------------------------------------------------------ Source: LinkedIn For paid promotions/collaborations to feature your leadership, feel free to contact us via direct message or email at leadershippharma@proton.me

Our Chairman and MD, Glenn Saldanha, and Christoph Stoller, President & Business Head – Europe & Emerging Markets, recently spent time with our teams in Malmo, Warsaw, and Watford. Their visit was an incredible opportunity for our teams to engage in insightful discussions, share key business updates, and align on our collective vision for growth and innovation.   At Glenmark, we remain committed to delivering high-quality medicines to patients worldwide. This leadership visit reaffirms our focus on strengthening our European presence, fostering collaboration, and driving excellence in everything we do. #Glenmark #GlenmarkEurope #LeadershipTeam #Collaboration Xavier Mesrobian Marco Cerato

We are happy to announce that Glenmark Pharma has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). To know more about this announcement, please visit: https://bit.ly/420fg6c #Glenmark #GlenmarkPharmaceuticals #PressRelease

We are proud to announce the successful conclusion of the 5th edition of the Glenmark Nutrition Awards, organized by our CSR arm Glenmark Foundation, in partnership with IDOBRO, UN Global Compact Network India, and IMPAct4Nutrition. With 403 entries from 22 states, spanning 168 districts, this year’s awards celebrated innovative and impactful initiatives transforming India’s nutrition landscape. These efforts reflect our deep commitment to nutrition and sustainability, in the fight against malnutrition. Together, we are shaping a future where every child is nourished, and every community thrives. Read more: https://bit.ly/3DArPvD #Glenmark #GlenmarkPharmaceuticals #Awards

We are happy to announce that Glenmark Therapeutics Inc., USA, has launched Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC); compare to the active ingredient in MiraLAX®2 Powder for Solution, 17 grams of Bayer HealthCare LLC. To know more about this announcement, please visit: https://bit.ly/4i9UiaG #Glenmark #GlenmarkPharmaceuticals #PressRelease

Celebrating the strength, resilience, and brilliance of every woman who challenges limits and drives change. Wishing you a Happy International Women’s Day! #Glenmark #GlenmarkPharmaceuticals #InternationalWomensDay

Our EVP & Business Head – Europe, Xavier Mesrobian, shares insights on Glenmark’s commitment to dermatology and skin health. With a strong legacy in innovation, we continue to advance care and support patients across Europe. Read more below!   #Glenmark #Dermatology #SkinHealth #Innovation